Pasar al contenido principal

Realistic analysis and molecular characterization of 3D epithelial organization

IJC2019-038819-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Incorporación
Convocatoria Juan de la Cierva Incorporación
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE SEVILLA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Microglia mitochondrial complex I deficiency during development induces glial dysfunction and early lethality

  • Mora-Romero, Bella
  • Capelo-Carrasco, Nicolas
  • Pérez-Moreno, Juan J.
  • Álvarez-Vergara, María I.
  • Trujillo-Estrada, Laura
  • Romero-Molina, Carmen
  • Romero-Molina, Carmen
  • Morano-Catalan, Noelia
  • Vizuete, Marisa
  • López-Barneo, José
  • Nieto-González, J.
  • García-Junco-Clemente, Pablo
  • Vitorica, Javier
  • Gutiérrez, Antonia
  • Macías, David
  • Rosales-Nieves, Alicia E.
  • Pascual Bravo, Alberto
Primary mitochondrial diseases (PMDs) are associated with pediatric neurological disorders and are traditionally related to oxidative phosphorylation system (OXPHOS) defects in neurons. Interestingly, both PMD mouse models and patients with PMD show gliosis, and pharmacological depletion of microglia, the innate immune cells of the brain, ameliorates multiple symptoms in a mouse model. Given that microglia activation correlates with the expression of OXPHOS genes, we studied whether OXPHOS deficits in microglia may contribute to PMDs. We first observed that the metabolic rewiring associated with microglia stimulation in vitro (via IL-33 or TAU treatment) was partially changed by complex I (CI) inhibition (via rotenone treatment). In vivo, we generated a mouse model deficient for CI activity in microglia (MGcCI). MGcCI microglia showed metabolic rewiring and gradual transcriptional activation, which led to hypertrophy and dysfunction in juvenile (1-month-old) and adult (3-month-old) stages, respectively. MGcCI mice presented widespread reactive astrocytes, a decrease of synaptic markers accompanied by an increased number of parvalbumin neurons, a behavioral deficit characterized by prolonged periods of immobility, loss of weight and premature death that was partially rescued by pharmacologic depletion of microglia. Our data demonstrate that microglia development depends on mitochondrial CI and suggest a direct microglial contribution to PMDs., B.M.-R. was the recipient of a ‘Junta de Andalucía’ predoctoral fellowship (2021), N.C.-C., M.I.A.-V. and E.M.M. were each the recipients of an FPU/FPI fellowship from the Spanish Ministry of Education (FPU20/03320, FPU15/02898 and PRE2019-087729) and J.J.P.-M. and A.E.R.-N. were the recipients of JdlC-I and JdlC-F fellowships from MCIN/AEI/ 10.13039/501100011033 (IJC2019-038819-I and FJCI-2015-23708). A.E.R.N. is funded by VII PPIT-US. This work was supported by grants to A.P., J.V., A.G. and D.M. by MCIN/AEI/ 10.13039/501100011033, ISCIII (FORT23/00008 (to A.P.); PI21/00915 (to J.V.); and PI21/00915 (to A.G.), and FEDER (RTI2018-096629-B-100, PID2021-126894OB-I00 ‘y por FEDER Una manera de hacer Europa’, SAF2017-90794-REDT, and PIE13/0004), by the regional Government of Andalusia (‘Proyectos de Excelencia’ P12‐CTS‐2138, P20_01312; BIOT22_00018_1, and ProyExcel_00845) co-funded by CEC, REC_EU and FEDER funds, and by the ‘Ayuda de Biomedicina 2018’, Fundación Domingo Martínez., Peer reviewed